24.01.2022 Cyprumed GmbH Enters Agreement with Ferring Pharmaceuticals for Development of Oral Drug Delivery Technology for Patient-Centric non-invasive Peptide Therapeutics Innsbruck, Austria – Cyprumed GmbH announced today that it has entered into a research and early development agreement with Ferring Pharmaceuticals for the development of next generation formulation technology for non-invasive delivery of biologics, with a focus on oral peptide delivery. Peptides and other large molecular therapeutics are usually delivered via injections. From a patient point of view, oral delivery is often the preferred option. A combination of Cyprumed´s proprietary oral formulation know-how with compounds approved for use in pharmaceutical products, providing protection against proteolytic degradation, and shared Ferring-Cyprumed knowledge on drug delivery development has already achieved important steps forward towards a new formulation technology for oral delivery of large macromolecular drugs such as peptides. The agreement will enable Ferring and Cyprumed to collaboratively develop drug delivery solutions that will facilitate the treatment of patients. "This agreement is a continuation and expansion of previous collaborative research projects between Cyprumed and Ferring. We believe that it will further strengthen ties between Cyprumed and Ferring and is an indicator for the potential of a long-term partnership between our two companies,” said Florian Föger, CEO of Cyprumed GmbH. “Cyprumed is confident that this partnership will contribute to the development of new treatment options for patients. It is exciting for us to announce the continuation of our partnership with Ferring, a company with a strong and unique research & development focus on peptide therapeutics.” “We are delighted to continue our collaboration with Cyprumed. Our work together over the last years has given rise to promising data and we are continuing to explore opportunities to deliver peptides orally, with the ultimate aim of improving patient care and helping people live better lives,” said Janet Halliday, Associate VP Ferring Controlled Therapeutics & External Technology. About Cyprumed GmbH Cyprumed GmbH is a privately held, Austrian based drug delivery company developing innovative proprietary drug delivery technologies with a focus on oral peptide delivery. An advantage of the Cyprumed technology is that it builds upon already approved pharmaceutical excipients. The Cyprumed technology is currently being evaluated in a number of collaborative feasibility studies. Cyprumed was founded in 2015. Initially, Cyprumed received financing funds from STARTUP.TIROL (previously CAST, Center for Academic Spin-offs Tyrol), from the Austrian Wirtschaftsservice GmbH (AWS – the Austrian Government Promotional Bank) and from the Austrian Research Promotion Agency (FFG). For more information on Cyprumed GmbH please visit https://www.cyprumed.net/new/ Cyprumed media contact: info@cyprumed.net

Hamburg, Deutschland – 21.01.2021 Der Innovationsführer im Bereich digitales Wärmemanagement, vilisto, sammelt mit der GLS Crowd eine Investitionssumme von 1,5 Millionen Euro in nur 11 Stunden und 37 Minuten ein. „Wir freuen uns sehr über diesen überwältigenden Erfolg“, sagt vilisto Gründer & CEO Christoph Berger, „er bestärkt uns, dass Klimaschutz und Wirtschaftlichkeit zusammengehören.“ Das schnelle Resultat zeigt, dass Crowdfunding als unkomplizierte Alternative zur zeitinvestiven VC-Finanzierung in der Mitte der Gesellschaft angekommen ist. Knapp 500 Investor*innen haben sich mit Beträgen zwischen 250 und 25.000 Euro an der Kampagne von vilisto beteiligt und bestätigen damit, dass die Nachfrage an Investitionen mit Impact hoch ist. „Immer mehr Menschen wollen ihr Geld sinnvoll anlegen, ohne dabei auf Rendite verzichten zu müssen“, sagt Berger. Die Kombination aus Wirtschaftlichkeit und Klimaschutzbeitrag ist auch für die Kund*innen ein entscheidendes Argument: „Energie zu sparen ist nicht nur aus finanzieller Sicht attraktiv, sondern auch nachhaltig und innovativ“, sagt beispielsweise Thorsten Römer, Geschäftsführer des Archäologischen Museums in Hamburg. Hier reduzieren die selbstlernenden Thermostate von vilisto durch bedarfsgerechtes Heizen den Energieverbrauch um 29,5%. Aktuell sparen über 100 Kundinnen mit vilisto Heizkosten und CO2-Emissionen. Mit dem Investment der GLS Crowd will das Unternehmen seinen ökologischen Impact verzweihundertfachen und vilisto zum Standard in öffentlichen und gewerblichen Gebäuden machen. Die Funding-Summe wird das Unternehmen nutzen, um das Vertriebs- und Marketingteam zu vergrößern, sowie bestehende Absatzkanäle weiter auszubauen. Deutschlandweit sind Kooperationen mit Vertriebs- und Installationspartnern geplant, um noch stärker zu skalieren. Auch die bestehende Technologie wird mit der Funding-Summe weiterentwickelt. „So treiben wir die Energiewende voran und schützen gemeinsam mit unseren Investorinnen das Klima“, sagt Christoph Berger. Infokasten vilisto GmbH Büros, Bildungseinrichtungen und Verwaltungsgebäude werden 80% der Zeit nicht genutzt – trotzdem bleibt die Heizung oft aufgedreht. Dieses Problem löst das digitale Wärmemanagement von vilisto:  Auf Basis der Schall-, Licht- und Bewegungssensoren im Thermostat erlernt der intelligente Algorithmus das tatsächliche Nutzungsprofil der Räume. So heizen die Thermostate morgens rechtzeitig vor und senken ab, wenn niemand mehr da ist. Alles vollautomatisiert und DSGVO-konform. Die vilisto GmbH wurde im April 2016 von Christoph Berger, Lasse Stehnken und Christian Brase gegründet. Sie hat ihren Sitz in Hamburg. Aktuell beschäftigt das Unternehmen 35 Mitarbeiter*innen. Infokasten GLS Crowd Die GLS Crowd ist die Online-Plattform für Crowdfinanzierungen, die Sinn machen. Die GLS Crowd verbindet Unternehmer*innen und deren zukunftsweisende Ideen mit Menschen, die mit ihrem Geld sozial-ökologische Projekte verwirklichen möchten. Investor*innen können online mit Beträgen ab 250 Euro in eine Vielfalt von nachhaltigen Projekten und jungen Wachstumsunternehmen investieren und haben dabei die Chance, am unternehmerischen Erfolg teilzuhaben. Kontakt: Christian Brase Leiter Marketing & Vertrieb brase@vilisto.de  +49 (0)40 / 3346 812-21 www.vilisto.de

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Biopharma and Clinical Research MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis by mass spectrometry, has raised €13.5m in a Series B financing round provided by Bruker Corporation (Nasdaq: BRKR). PreOmics was founded in 2016 by Dr. Garwin Pichler and Dr. Nils A. Kulak as a spin-out company from the laboratory of leading proteomics researcher Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried. PreOmics’ innovative sample processing technologies for mass spectrometry-based protein analysis are complementary to Bruker’s high-performance scientific instruments, as well as to proteomics mass spectrometry systems by other leading proteomics companies. Close collaboration synergies are expected to broaden the market opportunities for both PreOmics’ BeatBox platform technologies and Bruker’s timsTOF 4D proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for CRO and biopharmaceutical companies. Dr. Garwin Pichler, Co-Founder and Managing Director of PreOmics, commented: “We are excited to increase R&D, marketing and sales investments, and are pleased to have Bruker as a collaborator and major investor. Bruker shares our vision for advanced proteomic discovery processes for everyone, and a commitment to accelerate PreOmics’ growth. Our existing and future customers and partners will benefit from accelerated investments at PreOmics and from proteomics solution synergies to extend our product offerings and global presence.” Dr. Nils A. Kulak, Co-Founder and Managing Director of PreOmics, added: “We see a bright future for PreOmics’ research, development and commercialization efforts, now accelerated by the Series B primary investments and Bruker as partner and scientific collaborator. Our novel BeatBox technology is seamlessly compatible with PreOmics’ proteomic sample preparation technologies and in combination with the timsTOF Pro provides end-to-end workflows for processing of large tissue biobanks. Furthermore, we aim to develop integrated and automated BeatBox-based workflow solutions for every experience level and throughput need, while providing highest performance levels for unbiased, deep and comprehensive proteomics research.” In conjunction with the Series B financing, several early investors in PreOmics, such as High-Tech Gründerfonds (HTGF) and Think.Health Ventures, as well as certain business angels, have successfully sold their PreOmics shares to Bruker in a parallel secondary transaction, and Bruker is now a majority investor in PreOmics. Financial details of the secondary transactions were not disclosed. Dr. Bernd Goergen, Partner with HTGF, commented on the successful exit: “The fact that our time as a seed investor in Preomics has come to an end already after 5 years is a proof for the fantastic performance of both the management and the extremely innovative technology. Thank you, Garwin and Nils, for having us support a part of your journey. Joining forces with Bruker now paves BeatBox by PreOmics for high throughput tissue and cell homogenization 2 the way for setting gold standards in protein sample preparation and will make proteome analysis easier and more reliable than ever.” Dr. Michael Ruoff of Think.Health Ventures said: “Think.Health is grateful for having shared an important part of PreOmics’ success story, which will continue also beyond our investment with the great support by Bruker. We appreciate Garwin and Nils as exceptional scientists and visionary entrepreneurs – a rare combination that we definitely need more of in Germany.” Dr. Frank H. Laukien, President and CEO of Bruker Corporation, stated: “We are very pleased to invest in PreOmics, a leading proteomics sample preparation, automation and consumables company, with this Series B primary financing. By also acquiring a majority investment in PreOmics, Bruker further expands its proteomics vision to include the unique PreOmics sample preparation technologies, as well as more comprehensive, automated, robust and reproducible workflows and consumables for translational, biomarker and biopharma proteomics research.” About PreOmics GmbH PreOmics empowers our clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy, and commitment empower us to be both creative and quality focused – A trusted partner with deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition, and provide diagnoses that enhance lives and society. For more information, contact: Dr. Garwin Pichler, Founder & Managing Director PreOmics GmbH Phone: +49 (0) 89 / 23 14 163 – 0 Email: info@preomics.com Website: www.preomics.com Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany About Think.Health Ventures Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek for innovations and disruptive business models in digital healthcare, life sciences, pharmaceuticals and biotechnology. For more information please visit www.think-health.de. About High-Tech Gründerfonds High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies. Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, 3 Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG. www.htgf.de/en Media Contact High-Tech Gründerfonds Management GmbH Stefanie Grüter, Head of Marketing & Communications T.: +49 228 – 82300 – 188 s.grueter@htgf.de   Investor Contact High-Tech Gründerfonds Management GmbH Dr. Bernd Goergen, Partner T.: +49 228 – 82300 – 136 b.goergen@htgf.de